Navigation Links
Genstar Capital Appoints Mark Hanson to Managing Director
Date:12/21/2007

Firm's focus On Software & Software Services Yields Two Recent Transactions

SAN FRANCISCO, Dec. 21 /PRNewswire/ -- Genstar Capital, LLC, a middle market private equity firm that focuses on investments in selected segments of life sciences, healthcare services, industrial technology, software and software services, today announced the appointment of Mark Hanson as a Managing Director.

"We have been extremely pleased with Mark's leadership with two significant software and software services transactions since he joined our team one year ago as Operating Partner," said Jean-Pierre L. Conte, Chairman and Managing Director of Genstar. "Mark has extraordinary operational expertise with both large organizations as well as smaller, highly entrepreneurial businesses where he helped to successfully build the operations of a number of companies. We believe his experience and insights in the software industry and his intense operating background will help us to identify additional investment opportunities in what has become a core investment sector for Genstar and create superior returns for our investors."

Mr. Hanson joined Genstar as an Operating Partner in 2006 with more than 24 years of experience in the software industry and leads the firm's investments in Software and Software Services. Prior to joining Genstar, Mr. Hanson served as Senior Vice President for Corporate Development and Chief of Staff for Siebel Systems, Inc., where he worked closely with the executive team to help the company return to growth in 2005. He was responsible for building the M&A function at Siebel and during his tenure the company made 17 acquisitions. Prior to that, he was President and Chief Operating Officer of Visigenic Software, Inc., a company he helped build from a startup entity with no revenues, through its IPO and sale to Borland Software Corporation. He also worked as a senior executive with other leading software companies, including Sybase, Inc., Macromedia, Inc., and Informix Software, Inc. Mr. Hanson is a graduate of Santa Clara University and received his MBA degree from Golden Gate University.

Genstar has completed two acquisitions in 2007 in the software and software services sectors, including the purchase of ConvergeOne, one of the largest independent providers of business communications solutions in the U.S. and TravelCLICK, a leading global provider of interactive distribution solutions and marketing services to independent and chain hotels worldwide.

About Genstar Capital, LLC

Based in San Francisco, Genstar Capital (http://www.gencap.com) is a private equity investment firm that makes leveraged investments in quality middle- market companies. Genstar Capital works in partnership with management to transform its portfolio companies into industry-leading businesses. With more than $3 billion of committed capital under management and significant experience investing in businesses, Genstar focuses on selected segments of life sciences, healthcare services, industrial technology, software and software services.


'/>"/>
SOURCE Genstar Capital, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Y. (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, ... ILADS ) has disclosed that despite scientific studies, the Center for Disease Control ( ... chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution empowers ... process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  Interpace Diagnostics Group, ... provides clinically useful molecular diagnostic tests and pathology services, ... presented at the upcoming United States ... held March 4-10, 2017 in San Antonio, ... a review of data from the Company,s extensive experience ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
Breaking Medicine Technology: